ZLD for Pharmaceutical Manufacturing

Pharmaceutical manufacturing units face among the strictest ZLD requirements in Indian industry. CPCB's classification of API manufacturing as a red-category activity, combined with NGT orders protecting specific river systems and state PCB directions in pharma-intensive states like Telangana, Gujarat, and Himachal Pradesh, has effectively made ZLD a baseline compliance requirement for most Indian API manufacturers. The challenge is not simply treating high volumes of effluent — pharma units generate moderate volumes (100–2,000 m³/day) compared to textile or sugar industries — but treating effluent that contains a complex, changing mixture of API synthesis intermediates, process salts, residual solvents, and cleaning chemicals that challenges both biological treatment and membrane ZLD systems.

The primary complexity in pharmaceutical ZLD is the interaction of the organic compounds with RO membranes. Standard polyamide RO membranes — the workhorses of industrial ZLD — are effective salt rejectors but are vulnerable to fouling and chemical degradation by certain classes of organic compounds present in pharma effluent. Residual solvents (methanol, acetone, DCM, IPA) diffuse through membrane polymer layers, reducing mechanical integrity. API compounds with surfactant-like properties adsorb onto membrane surfaces, reducing permeate flux. Certain API compounds (particularly those with chelating functional groups) complex with iron present in membrane spacers, creating biofouling nucleation sites. Comprehensive pre-treatment designed specifically for pharmaceutical effluent characteristics — not generic industrial RO pre-treatment — is essential to achieve the 3–5 year membrane life required for ZLD economics to work.

Solvent management is a distinct requirement in pharmaceutical ZLD that does not arise in textile or food industry ZLD. API synthesis uses large volumes of organic solvents (methanol, ethanol, IPA, acetone, DCM, ethyl acetate, toluene) at different stages of synthesis and workup. Solvent recovery through distillation is standard practice in most API plants, but wash water containing residual solvents at 100–2,000 mg/L enters the ETP. Before this stream enters the RO stage, solvent concentrations must be reduced to <50 mg/L (for non-chlorinated solvents) or <10 mg/L (for chlorinated solvents) to prevent membrane damage. Biological treatment of biodegradable solvents (methanol, ethanol, acetone, IPA) through MBBR is effective at reducing solvent concentrations to these levels; chlorinated solvents (DCM, TCE) require steam stripping or activated carbon adsorption rather than biological treatment.

The ZLD process train for pharmaceutical manufacturing follows a defined sequence: effluent segregation (high-TDS API wash streams vs general facility streams), Fenton pre-treatment for recalcitrant API compounds (raising BOD:COD from 0.1–0.2 to 0.3–0.5), multi-stage MBBR biological treatment with extended HRT, activated carbon polishing for residual API removal and bioassay compliance, ultra-filtration (UF) membrane as an RO pre-treatment step (reducing SDI below 3), reverse osmosis at 60–65% recovery for TDS reduction, and MEE or MVR evaporation for RO reject concentration. The condensate from MEE evaporation (low TDS, low COD) is reused as utility water; the concentrated brine is processed through ATFD for dry salt cake disposal.

API campaign scheduling creates a unique operational challenge for pharma ZLD systems. Each API product has a different synthesis route, generating different waste streams with different inhibitory compounds, TDS levels, and recalcitrance characteristics. When a plant transitions from manufacturing one API to another, the ETP receives a completely different waste stream profile, potentially requiring different pre-treatment dosing, different MBBR acclimation periods, and different RO operating parameters. ZLD systems for multi-product API plants must be designed for the most challenging waste stream scenario, with flexible dosing and operating parameter adjustment capabilities. Pilot testing of each new API's waste stream before full-scale campaign discharge is strongly recommended.

Spans Envirotech designs pharmaceutical ZLD systems with specific attention to API compound characterisation, solvent management, and RO membrane protection. Our pharmaceutical ETP designs include full-stream characterisation protocols, Fenton treatability testing, and membrane fouling risk assessment for each client's specific API portfolio. We work with API manufacturers in the Hyderabad API cluster, Ankleshwar chemical zone, Baddi pharmaceutical SEZ, and Aurangabad MIDC, providing ZLD systems that address both the current API portfolio and future campaign flexibility requirements.